Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Gastroenterology and Hepatology

• Publication date

  2009-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cgh.2009.05.033PMID 19523535PMCID PMC3079239
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statistical Applications in Genetics and Molecular Biology

  2011cited by this paper
• Assessment of classification improvement in patients with Alzheimer's disease based on magnetoencephalogram blind source separation

  2008cited by this paper
• Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease

  2008cited by this paper
• Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography

  2008cited by this paper
• Review article: nonalcoholic fatty liver disease and hepatitis C virus – partners in crime

  2008cited by this paper
• Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD).

  2008cited by this paper
• The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

  2007cited by this paper
• FIB‐4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest

  2007cited by this paper
• Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages.

  2007cited by this paper
• Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index.

  2007cited by this paper
• Classifier Performance Estimation Under the Constraint of a Finite Sample Size: Resampling Schemes Applied to Neural Network Classifiers

  2007cited by this paper
• Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

  2007cited by this paper
• Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

  2006cited by this paper
• Long‐term follow‐up of patients with NAFLD and elevated liver enzymes

  2006cited by this paper
• Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

  2006cited by this paper
• Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies

  2006cited by this paper
• Assessment of liver fibrosis by a noninvasive method of transient elastography and biochemical markers.

  2006cited by this paper
• Comparison of simple tests for the non‐invasive diagnosis of clinically silent cirrhosis in chronic hepatitis C

  2006cited by this paper
• Screening for liver disease using non‐invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia

  2006cited by this paper
• FibroTest-FibroSURE™: towards a universal biomarker of liver fibrosis?

  2005cited by this paper
• Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers

  2005cited by this paper
• Histopathology of pediatric nonalcoholic fatty liver disease

  2005cited by this paper
• The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.

  2005cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women

  2005cited by this paper
• Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease.

  2005cited by this paper
• Sampling variability of liver biopsy in nonalcoholic fatty liver disease.

  2005cited by this paper
• Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non‐alcoholic fatty liver disease

  2005cited by this paper
• The histologic spectrum of nonalcoholic fatty liver disease.

  2004cited by this paper
• Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity

  2004cited by this paper
• Validity of the alcohol use disorders identification test in college students.

  2004cited by this paper
• Serum markers detect the presence of liver fibrosis: a cohort study.

  2004cited by this paper
• Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

  2003cited by this paper
• Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference

  2003cited by this paper
• Sampling variability of liver fibrosis in chronic hepatitis C

  2003cited by this paper
• Erratum: Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference (Hepatology (2003) 37 (1202-1219))

  2003cited by this paper
• Liver fibrosis in overweight patients.

  2000cited by this paper
• The apache III prognostic system: customized mortality predictions for Spanish ICU patients

  1998cited by this paper
• Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.

  1997cited by this paper
• The AUDIT questionnaire: choosing a cut-off score. Alcohol Use Disorder Identification Test.

  1995cited by this paper
• Comparison of Timeline Follow-Back and Averaging Methods for Quantifying Alcohol Consumption in Treatment Research

  1994cited by this paper
• Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors

  1990cited by this paper
• A method of comparing the areas under receiver operating characteristic curves derived from the same cases.

  1983cited by this paper

• Association between remnant cholesterol and cardiometabolic multimorbidity in non-alcoholic fatty liver disease patients: evidence from a cross-sectional study

  2026influential citation
• Integration of dual-energy computed tomography and radiomics to improve noninvasive assessment of liver fibrosis: A retrospective study.

  2026cites this paper
• Independent effects of exercise intensity on hepatic fat reduction in adults with metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial protocol.

  2026cites this paper
• Association between noninvasive hepatic fibrosis indices and heart failure mortality

  2026cites this paper
• Sensitivity and specificity of Magnetic Resonance Elastography in liver diseases in the pediatric age group.

  2026cites this paper
• Dynamic FIB-4 trajectory and a multi-state Markov model analysis reveal fibrosis progression and cardiovascular-cerebrovascular risk in MAFLD patients.

  2026cites this paper
• Fatty Liver Disease is a Silent Epidemic: Are We Doing Enough?

  2026cites this paper
• Prevalence of high-risk for advanced liver fibrosis using non-invasive scores among type 2 diabetes mellitus patients in the United Arab Emirates: a retrospective cross-sectional study.

  2026cites this paper
• Association of estimated liver fibrosis with carotid but not femoral atherosclerotic burden: the ILERVAS cohort

  2026cites this paper
• Prevalence and factors associated with metabolic dysfunction-associated fatty liver disease in a multiethnic Asian country

  2026cites this paper
• Metabolic dysfunction-associated steatotic liver disease and bone mineral density in type 2 diabetes mellitus: insights from a single-center cross-sectional study in North India

  2026cites this paper
• Circulating Thrombospondin-2 Levels Reflect Hepatic Fibrosis Severity and Renal Dysfunction in a General Population: Uku Study.

  2026cites this paper
• The Hepatic Steatosis Diagnostic Performance Using Attenuation Imaging With the Magnetic Resonance Imaging-Based Proton Density Fat Fraction as the Reference Standard: A Large, Prospective, Multicenter Cohort Study in Japan.

  2026cites this paper
• Effect of Direct-Acting Antivirals on Prognosis in Older Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Therapy: A Retrospective Study by the Red Cross Liver Study Group in Japan.

  2026cites this paper
• Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease

  2026cites this paper
• Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus in Tanzania: prevalence and predictors

  2026cites this paper
• Metabolic dysfunction-associated steatotic liver disease is associated with vascular dysfunction in type 1 diabetes.

  2026cites this paper
• Liver fibrosis scores predict cardiovascular outcomes in myocardial infarction and non-obstructive coronary arteries patients with and without diabetes or prediabetes.

  2026cites this paper
• Epidemiology and diagnostic of MASLD in Latin America: a yet to be met challenge

  2026cites this paper
• Type 2 Diabetes Mellitus and Risk of Advanced Fibrosis in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): The Results of Multi-centre Indian Consortium on MASLD (ICOM-D) Study.

  2026cites this paper
• Population estimates, trends, characteristics and prognostic outcomes of cardiovascular-kidney-liver-metabolic health: A population-based study

  2026influential citation
• Neither Metabolic Dysfunction Associated Steatotic Liver Disease Presence Nor Fibrosis Severity, By FIB4, Predicts Adverse Pregnancy Outcomes.

  2026cites this paper
• Menstrual Status After Liver Transplantation: An Underappreciated Predictor of Graft Liver Disease in Women Transplant Recipients

  2026cites this paper
• Nonalcoholic fatty liver disease assessed by multiple tools are correlated to periodontal conditions.

  2026cites this paper
• The prevalence and correlates of advanced fibrosis in patients with and without diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A cross-sectional study.

  2025cites this paper
• Non-invasive detection of fibrosis in non-alcoholic fatty liver disease by serum microfibrillar-associated protein 4 and its correlation with FIB-4 and transient elastography

  2025cites this paper
• Novel subtypes of metabolic associated steatotic liver disease linked to clinical outcomes: implications for precision medicine

  2025cites this paper
• Spontaneous Bacterial Peritonitis in Advanced Cirrhosis: Diagnosis by Tm Mapping and Inflammatory Profiles of Extracellular Vesicles

  2025cites this paper
• Comparison between vibration-controlled transient elastography and point shear wave elastography for assessment of hepatic fibrosis based on magnetic resonance elastography

  2025cites this paper
• Limitations of Guideline‐Recommended Risk Stratification in Identifying MASLD Patients for Novel Drug Treatments

  2025influential citation
• MRI-derived quantification of hepatic vessel-to-volume ratios in chronic liver disease using a deep learning approach

  2025cites this paper
• Transient elastography measurements of the liver and transplanted kidney in patients with AA amyloidosis: a cross-sectional comparative study

  2025influential citation
• Tips for Hepatologist Referral of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease with Alanine Aminotransferase Levels ≤ 30 U/L

  2025cites this paper
• Metabolic dysfunction-associated fatty liver disease (MAFLD) in the adult population attending a health check-up program in Thailand: prevalence and fibrosis status

  2025influential citation
• Metabolic-associated fatty liver disease: Noninvasive diagnosis and assessment of liver fibrosis

  2025cites this paper
• Complexity of metabolic dysfunction–associated steatotic liver disease: State of the art review

  2025cites this paper
• Managing Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care Settings: A Review

  2025cites this paper
• Evaluation of the Short-term Effect of Pemafibrate on Liver Fibrosis Biomarkers Stratified by FIB-4 Index in Patients with Type 2 Diabetes Mellitus and Hypertriglyceridemia

  2025cites this paper
• Hyperferritinemia and the Risk of Liver Fibrosis and Liver-Related Events in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease

  2025cites this paper
• The Fibrosis-4 Index (FIB-4) correlates with cardiovascular risk and insulin resistance in patients with rheumatoid arthritis.

  2025cites this paper
• Long-term outcomes of EUS–guided antegrade intervention with transmural and transanastomotic plastic stenting for benign bilioenteric anastomotic strictures (with video)

  2025cites this paper
• Association between alcohol consumption and hepatic fibrosis in Chinese adult males with metabolic dysfunction-associated steatotic liver disease

  2025cites this paper
• RENAL INJURY AND METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN PATIENTS WITH OBESITY

  2025cites this paper
• Dynamic changes in the characteristics of hepatocellular carcinoma among Japanese patients: Increasing incidence of cases without liver fibrosis

  2025influential citation
• Performance of the AASLD, EASL, and APASL Clinical Practice Guidelines in"grey zone"stages of Chinese patients with chronic hepatitis B

  2025cites this paper
• Higher Circulating Alpha-Klotho Levels Increase All-Cause Mortality Through Mediation Effects of Liver Fibrosis: A Second Analysis of NHANES.

  2025cites this paper
• Proactive case-finding and risk-stratification in people at risk of chronic liver disease in Greater Manchester: a cost-effectiveness analysis

  2025influential citation
• Steatotic Liver Disease as a Risk Enhancer in the Presence of Metabolic Syndrome.

  2025cites this paper
• Association Between Obstructive Sleep Apnea and Non-Alcoholic Fatty Liver Disease: Epidemiological Cross-Sectional Study and Mendelian Randomization Analysis

  2025cites this paper
• Prevalence and long-term outcomes of NAFLD and cardiovascular-kidney-metabolic health in the United States

  2025cites this paper
• Evaluating the Discriminative Performance of Noninvasive Biomarkers in Chronic Hepatitis B/C, Alcoholic Cirrhosis, and Nonalcoholic Cirrhosis: A Comparative Analysis

  2025influential citation
• Evaluation of the prevalence of MASLD, MASH and liver fibrosis in a Dutch bariatric cohort

  2025cites this paper
• Liver-related outcomes in patients with cirrhosis: The value of clinical and laboratory data and noninvasive tests

  2025cites this paper
• Prevalence of advanced liver fibrosis in the general population of the Paris region according to FIB-4 score and liver risk score

  2025cites this paper
• Mean Corpuscular Volume Is Correlated with Liver Fibrosis Defined by Noninvasive Blood Biochemical Indices in Individuals with Metabolic Disorders Aged 60 Years or Older

  2025cites this paper
• Higher afamin concentrations are associated with higher fatty liver indices: Population‐based KORA F4/FF4 study

  2025cites this paper
• Non-invasive scoring systems of liver fibrosis predict prognosis in the cohort with myocardial infarction

  2025cites this paper
• Steatosis Non-Invasive Tests Accurately Predict Metabolic Dysfunction-Associated Steatotic Liver Disease, While Fibrosis Non-Invasive Tests Fall Short: Validation in U.S. Adult Population.

  2025cites this paper
• Clinical performance of the Abbott Alinity anti-HBc immunoassay and its association with FIB-4 score in risk stratification of liver fibrosis.

  2025cites this paper
• Integrating systemic inflammation and liver biomarkers: prognostic implications of the ferritin index in heart failure

  2025influential citation
• Part 2: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Recommendations for Risk Stratifying Patients With MASLD

  2025influential citation
• Comparison of sarcopenia screening indices using serum creatinine and cystatin C in metabolic dysfunction-associated steatotic liver disease

  2025cites this paper
• The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a predictor of all cause and cardiovascular mortality in United States adults with NAFLD: a prospective cohort study

  2025influential citation
• Effects of Guselkumab on the FIB‐4 Index in Psoriasis Patients (EGIPT): A Three‐Year Study

  2025cites this paper
• Proteomic insights into metabolic dysfunction-associated steatotic disease: Identifying therapeutic targets and assessing on-target side effects.

  2025cites this paper
• Non-invasive Identification of Metabolic Dysfunction-associated Steatotic Liver Disease Patients eligible for Resmetirom Treatment.

  2025cites this paper
• Liver fibrosis marker is a potential predictor of the development of Fontan-associated liver diseases.

  2025cites this paper
• Hepatic extracellular volume fraction obtained by dual-energy CT: a comparison of 3 and 5 minute delayed phases and correlation with clinical data.

  2025cites this paper
• NPR is an independent risk factor for predicting all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease: evidence from NHANES 2007–2020

  2025influential citation
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association.

  2025cites this paper
• Advancing the Metabolic Dysfunction-Associated Steatotic Liver Disease Proteome: A Post-Translational Outlook

  2025influential citation
• Research Progress of the Relationship between Metabolic-Associated Fatty Liver Disease and Colorectal Neoplasia

  2025cites this paper
• Use of noninvasive fibrosis calculators in an urban diabetes center suggests a large burden of undetected advanced liver disease

  2025cites this paper
• The hepatocellular model of fatty liver disease: from current imaging diagnostics to innovative proteomics technologies

  2025cites this paper
• The pitfalls and significance of using ratios and calculated parameters in laboratory medicine.

  2025cites this paper
• Dynamic ALBI score and FIB-4 index trends to predict complications after resection of hepatocellular carcinoma: A K-means clustering approach.

  2025cites this paper
• The Value of Clinical Decision Support in Healthcare: A Focus on Screening and Early Detection

  2025cites this paper
• Utility of liver stiffness for the classification of portopulmonary hypertension in precapillary pulmonary hypertension.

  2025cites this paper
• Comparative association of MAFLD/MASLD and Subtypes with Cardiovascular Diseases Outcomes.

  2025cites this paper
• Liver fibrosis associated with more severe motor deficits in early Parkinson's disease.

  2025cites this paper
• Stronger associations of the phase angle than the TyG index with micro- and macrovascular complications in patients with type 2 diabetes

  2025influential citation
• Association of Index and Changes in Fibrosis-4 Score With Outcomes in Metabolic Dysfunction-Associated Steatohepatitis

  2025cites this paper
• Machine learning-based disease risk stratification and prediction of metabolic dysfunction-associated fatty liver disease using vibration-controlled transient elastography: Result from NHANES 2021–2023

  2025cites this paper
• Enhancing outcome prediction in patients with colorectal liver metastases undergoing hepatectomy: the synergistic impact of FIB-4 index and tumor burden score across KRAS profiles.

  2025cites this paper
• Survival Outcomes of Preoperative Serum Biomarkers in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma

  2025cites this paper
• HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study

  2025cites this paper
• Higher lifestyle oxidative balance scores are associated with lower metabolic dysfunction-associated fatty liver disease and fibrosis risk in US adults, while dietary scores have no impact on fibrosis

  2025influential citation
• Mortality for Any Hepatic Cause in People With Diabetes Compared to the Non‐Diabetic Population. A 10‐Year‐Observational Study

  2025cites this paper
• Redefining Liver Fibrosis Risk Assessment in Indians with Type 2 Diabetes: New FIB-4 Score Cutoff for Optimizing Sequential Assessment with Transient Elastography

  2025cites this paper
• The importance of patient engagement in the multimodal treatment of MASLD

  2025cites this paper
• Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction.

  2025cites this paper
• Effects of Tirzepatide on Patients With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study

  2025cites this paper
• Detecting at-risk steatotic liver disease and liver fibrosis in the community.

  2025cites this paper
• Exploring the Prevalence and Risk Factors of MASLD in Patients with Newly Diagnosed Diabetes Mellitus: A Comprehensive Investigation

  2025cites this paper
• Association between steatotic liver disease and microvascular complications in individuals with type 2 diabetes: a cohort study in the UK Biobank

  2025influential citation
• The impact of dapagliflozin on FIB-4 index over 2 years in patients with type 2 diabetes mellitus

  2025cites this paper
• The new assay type IV collagen 7S (CLEIA) is a useful test to identify progressive fibrosis in chronic liver disease: A study based on magnetic resonance elastography

  2025cites this paper
• Kronik karaciğer hastalıklarında FIB-4 ve APRI skorlarının klinik tanı ile uyumu

  2025cites this paper
• Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease

  2025influential citation
• FIB-4 predicts events in compensated advanced chronic liver disease and type 2 diabetes treated with GLP-1-receptor-agonists.

  2025cites this paper